SCHEMBL4802865

SCHEMBL4802865

CCCCCC(=O)Nc1nc2c(s1)CCCC2C(=O)N1CCN(c2ccccc2F)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.49
DRD3 P35462 1/20 0.49
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
HTR1A P08908 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 3/20 0.41
TSHR P16473 2/20 0.41
PLA2G1B P04054 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ATG4B Q9Y4P1 1/20 0.41
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 2/20 0.39
CACNA1G O43497 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3172493 0.85 MAPT (0.43) KMT2AALDH1A1LMNATSHRPLA2G1B
SCHEMBL4798494 0.79 RORC (0.40) DRD2HTR1ALMNASMN1; SMN2NPC1
SCHEMBL3170303 0.78 SMN1; SMN2 (0.45) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL3163269 0.77 DRD2 (0.40) DRD2KMT2AMEN1ALDH1A1LMNA
SCHEMBL3170296 0.77 SMN1; SMN2 (0.43) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL4801552 0.75 RORC (0.39) DRD2DRD3KMT2AMEN1KDM4E
SCHEMBL3162896 0.73 NPC1 (0.54) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL3171310 0.73 MAPT (0.53) KMT2AMEN1ALDH1A1LMNANPSR1
SCHEMBL3164100 0.73 LMNA (0.36) ALDH1A1LMNAMAPTTP53NPC1
SCHEMBL3157325 0.73 RORC (0.41) DRD2HTR1ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348347-B2 Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds GRUENENTHAL GMBH (DE) 2008-03-25 US claimed
US-20070027315-A1 Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds GRUENENTHAL GMBH (DE) 2007-02-01 US claimed
US-7348347-B2 Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds GRUENENTHAL GMBH (DE) 2008-03-25 US disclosed
US-20070027315-A1 Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds GRUENENTHAL GMBH (DE) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027315-A1 Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds TPH2, HTR6, TPH1 DRD2 1287/4885DRD3 1991/4885KMT2A 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.